Equasens Société anonyme (EQS) H1 2024 earnings summary

Executive summary

• H1 2024 revenue declined 4.1% year-over-year to €108.0m, with net profit attributable to the Group down 21.8% to €17.2m.

• Profit margins remained strong, with current operating income (COI) to sales at 19.3% reported and 20.0% like-for-like.

• Results were impacted by weaker economic conditions and ongoing investment in R&D, infrastructure, and sales.

Financial highlights

• Current operating income fell 24.1% year-over-year to €20.9m.

• Cash flow after interest and tax remained positive at €20.8m.

• Net financial surplus at 30/06/2024 stood at €87.9m, reflecting a change in IFRS 16 lease liabilities presentation.

Outlook and guidance

• Forecasts a return to revenue growth in H2 2024, with acceleration expected in 2025 as investments yield returns.

• Continued investment in R&D, infrastructure, and sales in France and Europe will temporarily impact 2024 profitability.

• Positioned for external growth opportunities in France and Europe, focusing on patient-centric and interoperable solutions.